David E. Griffith, MD Make an Appointment Ask a Question Refer Patient David E. Griffith, MD, is a pulmonologist at National Jewish Health. Dr. Griffith is in the Division of Mycobacterial & Respiratory Infections. Professor Division of Mycobacterial & Respiratory Infections Department of Medicine 5280 Top Doctors 2021 Previously a 5280 Top Doctor America’s Top Doctors 2015 — Castle Connolly, Medical, Ltd. Recognized in America’s Top Doctors — Castle Connolly, Inc. Best Doctors in America® 2019-2020 — Best Doctors, Inc. Recognized in Best Doctors in America® — Best Doctors, Inc. America’s Top Doctors 2020 — Castle Connolly Medical, Ltd. Email Profile Print Profile Overview Contact Info & Locations Patient Ratings & Comments Programs & Services Bronchiectasis Treatment Program Clinical Research Clinical Trials Department of Medicine Division of Mycobacterial and Respiratory Infections Mycobacterial and Respiratory Infections Mycobacterial Diseases Consult Service Tuberculosis Program Specialties & Conditions Bronchiectasis Chronic Obstructive Pulmonary Disease (COPD) Chronic Respiratory Infections Coping With Mycobacterial Disease Multi-Drug Resistant Organisms (MDRO) Tuberculosis (TB) Research Areas Bronchiectasis Nontuberculous Mycobacteria (NTM) Special Interests My major areas of interest spanning more than 30 years are mycobacterial diseases, including both nontuberculous mycobacterial (NTM) disease and tuberculosis, and bronchiectasis. I started my career in NTM lung disease with the invaluable encouragement of Dr. Richard Wallace more than 30 years ago. In the mid 1980’s there were very few centers interested in NTM lung disease in the United States or anywhere else in the world. Over the last 3 decades I have participated in multiple clinical trials and research projects that have resulted in the establishment of standards for treatment of patients with NTM diseases. I have been fortunate to work in the top two-referral centers for NTM disease in the United States where consultations are provided regionally and nationally to clinicians and patients. I have participated in the development of 3 iterations of nontuberculous mycobacterial disease diagnosis and treatment guidelines (1997, 2007, 2020) including as the principal author for the 2007 American Thoracic Society and Infectious Diseases Society of America Guidelines for the Diagnosis, Treatment and Prevention of Nontuberculous Mycobacterial Diseases. I am author or co-author on approximately 250 peer reviewed publications mostly pertaining to NTM disease including original research manuscripts, book chapters, reviews, editorials and electronic publications. Education Education 1974 - 1977 Baylor College of Medicine, Houston, TX 1970 - 1974 University of California, Santa Cruz, Santa Cruz, CA Internships 1977 - 1978 Baylor College of Medicine, Houston, TX Residency 1979 - 1980 Oregon Health & Sciences University, Portoland, OR 1978 - 1979 Baylor College of Medicine, Houston, TX Fellowship 1983 - 1985 Oregon Health & Sciences University, Portland, OR Awards & Recognition 2002-2019: W.A. and E.B. Moncrief Distinguished Professorship in Comprehensive Heart and Lung Research 2012: Murray Kornfeld Memorial Founders Lecture and Award, American College of Chest Physicians 2010-Present: Royal Society of Medicine, Overseas Fellow Board Certification 1980: Internal Medicine 1986: Pulmonary Medicine Professional Memberships Fellow American College of Physicians Fellow American College of Chest Physicians Overseas Fellow, Royal Society of Medicine American Thoracic Society Publications Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, Philley JV, Wallace RJ Jr, van Ingen J, Coulter C, Nezamis J, Winthrop KL; CONVERT Study Group. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT): A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018 Sep 14 Griffith DE, Flume PA, Thomson R, Mange K, Yuen DW, Morimoto K, Ruoss SJ, Codecasa LR, Yim Jae-Joon, Marras TK, van Ingen J, Wallace RJ, Brown Elliott BA, Coulter C, Winthrop KL.A Randomized, Open-Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Subjects with Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium avium Complex (MAC) That Are Refractory to Treatment (submitted) 104. Charles L. Daley, Jonathan M. Iaccarino, Christoph Lange, Emmanuelle Cambau, Richard J. Wallace Jr, Claire Andrejak, Erik C. Böttger, Jan Brozek, David E. Griffith, Lorenzo Guglielmetti, Gwen A. Huitt, Shandra L. Knight, Philip Leitman, Theodore K. Marras, Kenneth N. Olivier, Miguel Santin, Jason E. Stout, Enrico Tortoli, Jakko van Ingen, Dirk Wagner, Kevin L. Winthrop. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline (In press, Clinical Infect Dis) Winthrop KL, Flume PA, Thomson R, Mange K, Yuen DW, Morimoto K, Ruoss SJ, Codecasa LR, Yim Jae-Joon, Marras TK, van Ingen J, Wallace RJ, Brown Elliott BA, Coulter C, Griffith DE. Safety and Tolerability of Amikacin Liposome Inhalation Suspension in Treatment-Refractory Mycobacterium avium complex Lung Disease: A 12-Month Open-Label Extension Study (submitted) 55. Griffith DE, Aksamit T, Brown-Elliott B, Catanzaro, Daley C, A Gordin F, Holland S, Horsburgh, Huitt G, Iademarco M, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Jr. An Official ATS/IDSA Statement: Diagnosis, Treatment and Prevention of Nontuberculous Mycobacterial Diseases. Am J Respir Crit Care Med. 2007; 175: 367-416. Teaching & Professional Positions Professor of Medicine, University of TX Health Science Center, Tyler, TX Professor of Medicine, National Jewish Health Conflicts of Interest National Jewish Health physicians and scientists may collaborate with pharmaceutical or other industries to develop medical and scientific breakthroughs or to provide education on trends in quality medical practice and outcomes to physicians and health professionals around the country. National Jewish Health maintains a strict conflict of interest policy to ensure that all potential conflicts are clearly visible and that management plans are put in place in order to further innovation and education while ensuring the protection of our patients and the integrity of our research. National Jewish Health publicly discloses any payment to our physicians or scientists. View this faculty member’s industry relationships and collaborations. Ask a Question through Patient Portal Sign in to your My National Jewish Health patient portal account to communicate with your care team, manage appointments, and more. Create an Account Contact Information Office: 877.225.5654 Locations National Jewish Health Main Campus 1400 Jackson St. Denver, CO 80206 Patient Ratings The Patient Rating score is an average of all responses to care provider related questions on our independent rating system, the Press Ganey Patient Satisfaction Survey. This survey is about the patient care experience and does not address crucial characteristics like medical decision-making, prescribing the best therapy, and patient outcomes. Responses are measured on a scale of 1 to 5, with 5 being the best score. Learn more about our patient satisfaction survey. Comments Comments are collected in our Press Ganey Patient Satisfaction Surveys. Patients are de-identified to protect confidentiality and patient privacy. Learn more about our patient satisfaction survey.